Singulex Inc.’s SMC(Single Molecule Counting) cardiac troponin test can successfully track the risk of worsening cardiovascular disease in stable patients with recent acute coronary syndrome, results of a new study show.
Marc Bonaca of Harvard Medical School, and colleagues in the TIMI Study Group at Brigham And Women’s Hospital in Boston used the SMC technology to assess cardiac troponin levels in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?